Crohn's disease management in adults, children, and young people

This guideline intends to show the place of both new and established treatments in the wider care pathway for Crohn's disease. This will be useful for clinicians and people with Crohn's disease because new drugs have been licensed for Crohn's disease in the last decade. The guideline...

Full description

Bibliographic Details
Corporate Authors: National Clinical Guideline Centre for Acute and Chronic Conditions (Great Britain), Royal College of Physicians of London, National Institute for Health and Care Excellence (Great Britain)
Format: eBook
Language:English
Published: London Published by the National Clinical Guideline Centre at The Royal College of Physicians 10 October 2012, 2012
Series:Clinical guideline
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:This guideline intends to show the place of both new and established treatments in the wider care pathway for Crohn's disease. This will be useful for clinicians and people with Crohn's disease because new drugs have been licensed for Crohn's disease in the last decade. The guideline also deals with those medications which are unlicensed for treatment of the condition, but which have been used in this way (off-label) for many years and their role is recognised in other NICE documents as well as the British National Formulary. They include azathioprine, mercaptopurine and methotrexate. The guideline aims to help improve the care offered to people with Crohn's disease and provide information about the clinical and cost effectiveness of potential care pathways. Management of Crohn's disease in specific populations (for example, in pregnancy) may require special consideration
Item Description:Title from PDF title page
Physical Description:1 PDF file (398 pages) illustrations